Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
Parkinson Disease, Parkinson Disease Dementia
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring cognitive impairment, Parkinson disease dementia, wearable sensor, gait analysis, rivastigmine, cholinesterase inhibitor
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years.
- Diagnosis of idiopathic Parkinson disease.
- Mild to moderate cognitive impairment, as determined by a MoCA score of ≤ 25 and ≥ 10.
- Patient passes the Evaluation to Sign Consent (ESC) or a legally authorized representative (LAR) is present at the time of enrollment and signs the informed consent form on behalf of the patient.
- Patient is enrolled (or willing to be enrolled) in the University of Maryland Parkinson Disease and Movement Disorders Center PD Research Database (HP 42195)
Exclusion Criteria:
- Advanced Parkinson disease (Hoehn & Yahr stage 5), with inability to walk unassisted.
- Other medical condition(s) that significantly interfere(s) with gait and balance (e.g., advanced arthritis).
Sites / Locations
- University of Maryland School of Medicine, Dept. of Neurology
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Arm 1: baseline only (cross-sectional)
Arm 2: rivastigmine (longitudinal)
At baseline, all participants will undergo instrumented gait/balance testing, using a wearable sensor (Dynaport MT), and cognitive testing, using a computerized cognitive test battery (NeuroTrax Mild Cognitive Impairment & Early Dementia Battery by MindStreams). In other words, all participants will be part of arm 1.
As study intervention, a subgroup of participants will then be treated with transdermal rivastigmine patch for 12 weeks, with dose increases every 4 weeks and titration up to 13.3 mg/24h, if tolerated. For the arm 2 subgroup of participants, the same assessment that was performed at baseline (quantitative gait testing and NeuroTrax computerized cognitive test battery) will be repeated after 12 weeks, with the patient on a stable dose of transdermal rivastigmine.